BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 25, 2012
 |  BioCentury  |  Finance

Taking heart in darapladib

How Human Genome calculates bigger takeout price than GSK's $13 offer

Investors may be losing faith that Human Genome Sciences Inc. can get more from an acquirer than the $13 per share offer on the table from partner GlaxoSmithKline plc.

HGS shares rose to $14.70 in mid-May, a month after GSK's $2.6 billion bid. By mid-June, when the biotech was wrapping up a strategic review process in which it evaluated takeover offers, the stock went as low as $13.10. Last week, HGS closed down $0.16 to $13.35.

At the Goldman Sachs conference in early June, HGS EVP and CFO David Southwell made the case for...

Read the full 460 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >